Scinopharm Taiwan (TPE:1789) EPS (Basic): NT$0.17 (TTM As of Dec. 2025)


TPE:1789 Scinopharm Taiwan Ltd TPE:1789
76 GF Score
Price NT$20.55
GF Value NT$27.02
Valuation Modestly Undervalued
! 7 Warning Signs
View Full Analysis

What is Scinopharm Taiwan EPS (Basic)?

Scinopharm Taiwan TPE:1789 +1.73% 76 EPS (Basic) is NT$0.17 as of Dec. 2025. GuruFocus rates TPE:1789 with a GF Score™ of 76/100 and a GF Value™ of NT$27.02 (Modestly Undervalued). The stock has 7 warning signs investors should review.

Scinopharm Taiwan's basic earnings per share (Basic EPS) for the three months ended in Dec. 2025 was NT$0.05. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.17.

Scinopharm Taiwan's EPS (Diluted) for the three months ended in Dec. 2025 was NT$0.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$0.17.

Scinopharm Taiwan's EPS without NRI for the three months ended in Dec. 2025 was NT$0.05. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was 0.17.

During the past 12 months, Scinopharm Taiwan's average EPS without NRIGrowth Rate was -60.60% per year. During the past 3 years, the average EPS without NRI Growth Rate was -27.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -8.20% per year. During the past 10 years, the average EPS without NRI Growth Rate was -10.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Scinopharm Taiwan's highest 3-Year average EPS without NRI Growth Rate was 18.60% per year. The lowest was -31.20% per year. And the median was -11.60% per year.

Scinopharm Taiwan  (TPE:1789) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Scinopharm Taiwan EPS (Basic) Related Terms

Scinopharm Taiwan EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Scinopharm Taiwan's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scinopharm Taiwan EPS (Basic) Chart

Scinopharm Taiwan Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.31 0.45 0.36 0.43 0.17

Scinopharm Taiwan Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.06 0.04 0.02 0.05
TPE:1789
76GF Score
Scinopharm Taiwan Ltd TPE:1789
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scinopharm Taiwan EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Scinopharm Taiwan's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(136.951-0)/790.739
=0.17

Scinopharm Taiwan's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(41.281-0)/790.739
=0.05

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of NT$0.17 mean?
Scinopharm Taiwan (TPE:1789) has a EPS (Basic) of NT$0.17 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Scinopharm Taiwan and its competitors.
Is Scinopharm Taiwan's EPS (Basic) too high?
Scinopharm Taiwan's current EPS (Basic) is NT$0.17. Overall, Scinopharm Taiwan has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Scinopharm Taiwan's EPS (Basic) compare to ZTS?
Scinopharm Taiwan's EPS (Basic) of NT$0.17 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Scinopharm Taiwan and its competitors. Scinopharm Taiwan's current EPS (Basic) is NT$0.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scinopharm Taiwan stock overvalued right now?
Based on GuruFocus' analysis, Scinopharm Taiwan (TPE:1789) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$27.02, compared to a current price of NT$20.55 — trading 23.9% below its estimated fair value. The current EPS (Basic) is NT$0.17. Scinopharm Taiwan's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Scinopharm Taiwan (TPE:1789), the current EPS (Basic) is NT$0.17 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Scinopharm Taiwan (TPE:1789) Overvalued in 2026?

Based on GuruFocus' analysis, Scinopharm Taiwan stock appears to be undervalued. The current stock price of NT$20.55 is trading 23.9% below its estimated GF Value™ of NT$27.02. GuruFocus considers Scinopharm Taiwan to be Modestly Undervalued.

Key valuation signals for TPE:1789:

  • EPS (Basic): NT$0.17
  • GF Value™: NT$27.02 vs. price of NT$20.55 (23.9% below fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the TPE:1789 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Scinopharm Taiwan Business Description

Address Nan-Ke 8th Road, No. 1, Southern Taiwan Science Park, Shan-Hua, Tainan, TWN, 74144
Scinopharm Taiwan Ltd is mainly engaged in the manufacture of western medicines and other chemical materials, biological technology services, intellectual property rights, international trade, and the research, development, production, manufacture, and sales of Active Pharmaceutical Ingredients (API), albumin medicines, oligonucleotide medicines, peptide medicines, injections, and new small molecule drugs. The Company also provides related consulting and technical services and international trade for the above products. In addition, the Company sells chemical material reprocessed from material recycled from the Company's manufacturing process.
76GF Score

Get the complete analysis for TPE:1789

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$20.55
Price
NT$27.02
GF Value